IMNN: Updated OVATION 2 Data Shows 14.7-Month Improvement in OS Compared to SoC [Yahoo! Finance]
IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY
Imunon (NASDAQ:IMNN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.